Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1999 1
2003 3
2004 4
2005 2
2006 1
2007 1
2008 1
2009 2
2010 2
2012 1
2014 1
2015 1
2016 1
2018 3
2020 1
2022 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Red cell substitutes from hemoglobin--do we start all over again?
Kluger R. Kluger R. Curr Opin Chem Biol. 2010 Aug;14(4):538-43. doi: 10.1016/j.cbpa.2010.03.021. Epub 2010 Apr 12. Curr Opin Chem Biol. 2010. PMID: 20392662 Review.
Evaluation of clinical trials of all products led to the conclusion that none that were tested would be suitable for clinical use [Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM: Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and de …
Evaluation of clinical trials of all products led to the conclusion that none that were tested would be suitable for clinical use [Natans …
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
Haley M, Cui X, Minneci PC, Deans KJ, Natanson C, Eichacker PQ. Haley M, et al. Curr Opin Infect Dis. 2004 Jun;17(3):205-11. doi: 10.1097/00001432-200406000-00006. Curr Opin Infect Dis. 2004. PMID: 15166822 Review.
This review highlights emerging insights into the biology of protein C and activated protein C in sepsis, summarizes additional analysis growing out of the phase III trial testing recombinant human activated protein C, and assesses the cost-effectiveness that …
This review highlights emerging insights into the biology of protein C and activated protein C in sepsis, summarizes additiona …
Recombinant human activated protein C in sepsis: assessing its clinical use.
Haley M, Cui X, Minneci PC, Deans KJ, Natanson C, Eichacker PQ. Haley M, et al. Am J Med Sci. 2004 Oct;328(4):215-9. doi: 10.1097/00000441-200410000-00004. Am J Med Sci. 2004. PMID: 15486536 Review.
Based on the results of the phase III PROWESS trial, recombinant human activated protein C (rhAPC) was approved by the Food and Drug Administration (FDA) for use in severely septic patients. ...
Based on the results of the phase III PROWESS trial, recombinant human activated protein C (rhAPC) was approved by the Food and Drug …
Novel therapies for sepsis: a review.
Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Deans KJ, et al. J Trauma. 2005 Apr;58(4):867-74. doi: 10.1097/01.ta.0000158244.69179.94. J Trauma. 2005. PMID: 15824673 Review.
As a class, the anticoagulant agents do not improve survival; however, the efficacy of these agents may have been confounded by concurrent heparin therapy. Activated protein C demonstrated a beneficial effect on survival that was dependent on severity of illness. ...
As a class, the anticoagulant agents do not improve survival; however, the efficacy of these agents may have been confounded by concurrent h …
Once is not enough: clinical trials in sepsis.
Sweeney DA, Danner RL, Eichacker PQ, Natanson C. Sweeney DA, et al. Intensive Care Med. 2008 Nov;34(11):1955-60. doi: 10.1007/s00134-008-1274-6. Epub 2008 Oct 7. Intensive Care Med. 2008. PMID: 18839140 No abstract available.
Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis.
Minneci P, Deans K, Natanson C, Eichacker PQ. Minneci P, et al. Eur J Clin Microbiol Infect Dis. 2003 Jan;22(1):1-9. doi: 10.1007/s10096-002-0857-3. Epub 2003 Jan 28. Eur J Clin Microbiol Infect Dis. 2003. PMID: 12582737 Review.
In contrast to mediator-specific anti-inflammatory agents, glucocorticoids and activated protein C have recently demonstrated significant beneficial effects in individual clinical trials. ...Furthermore, consistent with earlier findings for mediator-specific anti-inflammat …
In contrast to mediator-specific anti-inflammatory agents, glucocorticoids and activated protein C have recently demonstrated signifi …
32 results